Researchers at Northwestern University, USA, have succeeded in finding a drug that can clear psoriasis in the body, almost completely and the great majority of the responses persist at least 60 weeks . The new drug called ixekizumab, tradename Taltz ® , is a monoclonal antibody, prescribed to those with moderate to severe psoriasis. Research published in the prestigious journal, New England Journal of Medicine ; reports the results of 3 large, long-term clinical trials which saw 80% of patients psoriasis completely or almost completely cleared. Psoriasis affects 3% of the world population. It is an immune-mediated inflammatory disease and its most significant symptom is itchy, dry and red skin. Accompanying those uncomfortable symptoms, psoriasis is also associated with an increased risk of depression, heart disease, and diabetes. What are Phase 3 trials? ( Understanding the Drug Discovery Process- Compound Interest ) "Usually 1000-3000 people, gauge